Question · asked by 1 review
Oral dehydroepiandrosterone vs placebo: Adverse events: severe
- Population
- patients with cutaneous disease in systemic lupus erythematosus
- Intervention
- Oral dehydroepiandrosterone
- Comparison
- placebo
- Outcome
- Adverse events: severe
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Oral dehydroepiandrosterone vs placebo Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty). Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane Headline outcomes only | RR 0.09 [0.01, 1.66] | 1 study · 381 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.